DIAGNOSTICS DNA Sciences Vies for Viability | GenomeWeb

Contrary to the fanfare surrounding its launch by Silicon Valley celeb Jim Clark four years ago, DNA Sciences hasn’t had what you would call an auspicious start. Consider its crisis-ridden last 20 months: In February 2001 COO Gregory Went resigned; five months later the company withdrew its IPO; next, the board ousted CEO Hugh Reinhoff; and most recently CSO Ray White departed for the Ernest Gallo Clinic, though he’ll remain on DNA Sciences’ board. The company has shrunk its staff from a high of 175 down to a tidy 60.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.